Company Description
ENDRA Life Sciences Inc. develops technology for improving the capabilities of clinical diagnostic ultrasound.
The company develops thermo-acoustic enhanced ultrasound technology that transmits sound waves, which bounce off tissues, organs, and blood in the body for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion.
It also offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding.
The company has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.
| Country | United States |
| IPO Date | May 9, 2017 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 21 |
| CEO | Francois Michelon |
Contact Details
Address: 3600 Green Court, Suite 350 Ann Arbor, Michigan 48105 United States | |
| Phone | 734-335-0468 |
| Website | endrainc.com |
Stock Details
| Ticker Symbol | NDRA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001681682 |
| CUSIP Number | 29273B104 |
| ISIN Number | US29273B3024 |
| Employer ID | 26-0579295 |
| SIC Code | 3845 |
Key Executives
| Name | Position |
|---|---|
| Francois Michelon | Chairman, President and Chief Executive Officer |
| Irina Pestrikova | Senior Director of Finance and Secretary |
| Michael Thornton Ph.D. | Chief Technology Officer |
| Dr. Jonathan Behr Ph.D. | Co-Founder |
| Steve Freeman | Human Resources Leader |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 19, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Apr 3, 2024 | EFFECT | Notice of Effectiveness |
| Apr 3, 2024 | 424B5 | Filing |
| Apr 3, 2024 | 424B5 | Filing |
| Mar 28, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 28, 2024 | S-3/A | [Amend] Registration statement under Securities Act of 1933 |
| Mar 28, 2024 | 10-K | Annual Report |
| Mar 28, 2024 | 8-K | Current Report |
| Feb 14, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Dec 29, 2023 | 424B3 | Prospectus |